A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells
- PMID: 21233838
- PMCID: PMC3089835
- DOI: 10.1038/leu.2010.300
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3089835/bin/leu2010300f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3089835/bin/leu2010300f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3089835/bin/leu2010300f3.gif)
Similar articles
-
Multiple myeloma-initiating cells.Int J Hematol. 2013 Mar;97(3):306-12. doi: 10.1007/s12185-013-1293-0. Epub 2013 Feb 19. Int J Hematol. 2013. PMID: 23420183 Review.
-
Promises and challenges of MicroRNA-based treatment of multiple myeloma.Curr Cancer Drug Targets. 2012 Sep;12(7):838-46. doi: 10.2174/156800912802429355. Curr Cancer Drug Targets. 2012. PMID: 22671926 Free PMC article. Review.
-
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.Blood. 2009 Apr 30;113(18):4309-18. doi: 10.1182/blood-2008-10-183772. Epub 2009 Feb 4. Blood. 2009. Retraction in: Blood. 2010 Apr 8;115(14):2983. doi: 10.1182/blood-2010-03-273136. PMID: 19196658 Free PMC article. Retracted.
-
Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis.Exp Hematol. 2007 Oct;35(10):1477-8. doi: 10.1016/j.exphem.2007.06.012. Epub 2007 Aug 3. Exp Hematol. 2007. PMID: 17681665 No abstract available.
-
Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.Am J Pathol. 2004 Feb;164(2):747-56. doi: 10.1016/S0002-9440(10)63162-8. Am J Pathol. 2004. PMID: 14742278 Free PMC article.
Cited by
-
Establishment of A Three-Dimensional Culture Condition for The U266 Cell Line Based on Peripheral Blood Plasma-Derived Fibrin Gels.Cell J. 2023 Apr 1;25(4):229-237. doi: 10.22074/cellj.2023.562849.1138. Cell J. 2023. PMID: 37210643 Free PMC article.
-
Animal Models of Multiple Myeloma Bone Disease.Front Genet. 2021 Jun 7;12:640954. doi: 10.3389/fgene.2021.640954. eCollection 2021. Front Genet. 2021. PMID: 34163520 Free PMC article. Review.
-
Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.Front Immunol. 2021 Jun 2;12:667054. doi: 10.3389/fimmu.2021.667054. eCollection 2021. Front Immunol. 2021. PMID: 34149703 Free PMC article. Review.
-
JunB is a key regulator of multiple myeloma bone marrow angiogenesis.Leukemia. 2021 Dec;35(12):3509-3525. doi: 10.1038/s41375-021-01271-9. Epub 2021 May 18. Leukemia. 2021. PMID: 34007044 Free PMC article.
-
Management of Myeloma Bone Lesions.Int J Mol Sci. 2021 Mar 25;22(7):3389. doi: 10.3390/ijms22073389. Int J Mol Sci. 2021. PMID: 33806209 Free PMC article. Review.
References
-
- Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860–1873. - PubMed
-
- Tassone P, Tagliaferri P, Fulciniti MT, Di Martino MT, Venuta S. Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues. Curr Pharm Des. 2007;13:487–496. - PubMed
-
- Dalton W, Anderson KC. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin Cancer Res. 2006;12:6603–6610. - PubMed
-
- Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997;90:754–765. - PubMed
-
- Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92:2908–2913. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical